Ladiratuzumab vedotin Antibody
Ladiratuzumab vedotin is an antibody-drug conjugate targeting LIV-1 for breast cancer research. It delivers the cytotoxic agent MMAE, demonstrating potent in vitro activity and inducing immunogenic cell death. Its mechanism is being investigated in both cellular assays and in vivo models.
Product Specifications
Target
Antibody-Drug Conjugates (ADCs)
Clonality
Monoclonal
Conjugation
Unconjugated
Concentration
10.92 mg/mL
Purity
95.00% (May vary between batches)
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC940460-100 1x 100 µL
CD44 Standard (156-3C11), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740270-500 1x 500 µL
Fibronectin (HFN7.1), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040012-100 1x 100 µL
Tyrosinase (T311), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC681820-100 1x 100 µL
Ep-CAM / CD326 (Epithelial Marker) (rVU-1D9), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740034-100 1x 100 µL
Cytokeratin 8/18 (C-51), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040775-500 1x 500 µL
Pgp9.5 (UCHL-1) (UCHL1/775), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details